Trials / Completed
CompletedNCT05918809
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,031 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) therapy among patients with DLBCL.
Conditions
Timeline
- Start date
- 2021-07-25
- Primary completion
- 2022-06-17
- Completion
- 2022-06-17
- First posted
- 2023-06-26
- Last updated
- 2023-06-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05918809. Inclusion in this directory is not an endorsement.